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FAMILY HISTORY, BRCA1/BRCA2 STATUS, AND LOCAL RECURRENCE IN
CONSERVATIVELY TREATED BREAST CANCER PATIENTS. Elizabeth V.
Harrold, Ellen T. Matloff, Bruce C. Turner, and Bruce G. Haffty. Department of
Therapeutic Radiology, Yale University School of Medicine, New Haven, CT.
This study explores the relationship among young age at diagnosis, family
history, BRCAl/2 status, and ipsilateral breast tumor relapse (IBTR) in
conservatively treated breast cancer patients. First, age was examined as a
prognostic factor for IBTR using clinical information from 984 patients in a
computerized database. Second, 52 case patients who had experienced an IBTR
were matched to 52 control patients from the database to determine if IBTR was
associated with family history. For these 104 patients, detailed family history
interviews were conducted; all data were recorded in a pedigree. A genetic
counselor blind to the clinical histories then scored each pedigree as highly
suggestive, moderately suggestive, or not suggestive of a hereditary breast
cancer. Third, to assess the role of BRCAl/2 status in IBTR, 52 case patients and
15 control patients underwent genetic testing. For the database, the overall
actuarial 10-year survival was 73% with a median follow-up of 12.3 years; 112
patients had experienced a local relapse resulting in a 10-year actuarial IBTR rate
of 15%. Patients age 40 and younger had a significantly higher IBTR rate than
patients over age 40 (p<0.001). In the family history study, no differences were
found between the cases and the controls. The BRCAl/2 mutation rate was 15%
in the IBTR group (n=52). However, 40% of case patients age 40 and younger
had mutations, compared to 6.6% of matched controls. In summary, young age
at diagnosis is a significant risk factor for IBTR but family history is not. Young
patients with IBTR have an elevated frequency of BRCAl/2 mutations; the IBTRs
in these patients may represent new primaries, which has implications for
mutation carriers considering lumpectomy and radiation therapy.
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1INTRODUCTION
Breast cancer accounts for almost one in every three cancers diagnosed in
women, making it the most common cancer among women aside from skin
cancers (1). According to the American Cancer Society, approximately 175,000
women in the United States were diagnosed with invasive breast cancer in 1999,
with an additional 40,000 cases of in situ breast cancer. In 1999, an estimated
43,300 women died of breast cancer (1).
Over the past three decades, the clinical management of breast cancer has
seen significant changes. In the 1970s, most patients presented with palpable
tumors and underwent mastectomy plus or minus radiation therapy (2). At
present in the year 2000, conservative management of breast cancer with
lumpectomy followed by radiation therapy is the preferred standard of care for
the vast majority ofwomen with early stage breast cancer. At Yale-New Haven
Hospital, conservative treatment has been used with increasing frequency since
the 1960s (3). Several prospective randomized clinical trials (4 - 7), as well as
retrospective series (8 - 10), have consistently demonstrated acceptable outcomes
for patients treated with lumpectomy and radiation therapy. Research has
demonstrated no statistically significant survival differences between patients
treated with lumpectomy and radiation therapy and patients treated with
modified radical mastectomy. These studies, both individually and collectively,
have shown that the disease-free survival, distant disease-free survival, and
overall survival are equivalent for conservative management and mastectomy for
women with early stage breast cancer (6-11).
Long term follow-up studies, however, have also invariably revealed
significant rates of local relapse, or ipsilateral breast tumor recurrence (IBTR)
2following conservative treatment. For example, in a series of 536 cases at MD
Anderson Cancer Center, the actuarial IBTR rate was 9% at 5 years and 19% at 10
years (12). Fourquet et al report an actuarial IBTR rate of 7% at 5 years, 11% at 10
years, and 18% at 15 years for 518 patients (9). At Yale, the actuarial IBTR rate
has been reported as 8% at 5 years (3) and 16% at 10 years (13). Fisher et al report
a 10% cumulative incidence of IBTR at 12 years (5). Veronesi et al estimate the
yearly probability of IBTR to be approximately 1% up to the 10th year following
surgery (14). In summary, most institutions have observed actuarial IBTR rates
of between 0.5% and 2% per year with a plateau between 10% and 20% at 10 to
15 years (3, 5, 9, 10, 12 - 15).
The majority ofwomen with local relapse are able to undergo successful
salvage mastectomy. The issue of survival after IBTR has been controversial;
some studies have suggested that IBTR is a significant independent predictor of
distant metastasis and mortality (13, 14, 16, 17). However, these researchers
agree that IBTR is probably a marker of risk for, rather than a cause of, distant
metastasis or decreased survival (16). In contrast, others have found no decrease
in survival following IBTR (15, 18). Kurtz et al state that local recurrences are
"highly operable" and are "associated with a favorable prognosis" (18). Studies
estimate the survival after IBTR to be approximately 70% at 5 years (14) and 64%
at 10 years following salvage mastectomy (18). Irrespective of the possible
deleterious effect of IBTR on survival, experiencing a recurrence of disease
impacts on a woman's quality of life and brings with it extensive psychological,
medical, and financial repercussions. The salvage mastectomy also defeats the
original goal of breast preservation. Thus, as the technique of lumpectomy and
radiation therapy has become more widespread, the obstacle of local relapse has
become increasingly important for the clinical oncologist. An active area of
investigation lies in determining the risk factors for IBTR.
3Numerous studies have examined both clinical and pathologic features
that may predict for local recurrence. Significant prognostic factors include the
size and histologic grade of the tumor, multicentricity, the status of the margins,
the timing of radiation therapy, and the overexpression of certain growth factors
and oncoproteins (14, 19, 20, 21). Some studies have found major lymphocytic
stromal reaction to be a significant risk factor for IBTR (19), as well as
peritumoral lymphatic invasion (14, 22), endolymphatic extension (9), and an
extensive intraductal component (7). Insulin-like growth factor-I receptor
overexpression has been demonstrated with early IBTR (20). In a case-control
study, local relapses were associated with elevated levels of HER-2 neu
oncoprotein within the primary tumors (21).
Although much of the research on clinical and pathologic characteristics
has been inconsistent and sometimes conflicting (21), one of the most consistently
reported risk factors for local relapse has been young age at diagnosis (3, 7, 9, 10,
12, 14, 15, 18, 23, 24). Published in 1981, the Institute Curie first noted a higher
rate of local relapse in younger women (15). In this retrospective study (n=314),
the incidence of IBTR at 3 years was 35% in patients age 30 and younger, as
compared to zero in patients over age 50 (15). In 1987, Delouche et al reported
local-regional recurrences in 19.7% of patients age 40 and younger, versus 6.8%
in patients over age 40 with a median follow-up of 11 years (10). The following
year, Kurtz et al reported an IBTR rate of 19% in patients younger than age 40,
versus 9% in older patients, also with a median follow-up of 11 years (18). In a
multivariate analysis from the Institute Curie in 1989, independent prognostic
factors for IBTR included young age, inadequate surgical excision, and
endolymphatic extension (9). Age was the most important prognostic factor; 10
years after diagnosis, patients older than age 55 had a 97% probability of being
4free from IBTR, whereas patients age 32 or younger had only a 71% probability
of being free from IBTR (9).
Whether young age is associated with decreased overall survival has yet
to be firmly established. Some studies have found no differences in survival for
younger patients (12, 18). For example, one study reports a 15-year survival of
76% for younger patients and 75% for older patients (18). On the other hand, a
recent study found that women age 35 or younger have both significantly higher
local recurrence rates and lower overall survival rates (24). However, Kim and
colleagues conclude that the decreased survival rate is not due to the local
recurrence (24). In another study, younger patients had decreased overall
survival and disease-free survival compared to their older counterparts (25). To
quote Chung et al, "[Our study] suggests that, stage for stage, young women
have more aggressive disease than older women" (25). Young patients have been
noted to have a higher incidence of adverse histopathologic characteristics, such
as major lymphocytic stromal reaction and an extensive intraductal component
(19). The poor prognosis in young women may be related to these factors but the
exact mechanism remains unknown.
As outlined, research has repeatedly shown that young age is an
independent risk factor for local relapse following lumpectomy and radiation
therapy. This observation may be crucial to the lives of young breast cancer
patients, many ofwhom would elect to undergo conservative treatment as
opposed to mastectomy if given the choice. One might hypothesize that family
history, another factor associated with young age, could play a role in the
propensity of young women towards local relapse. Young age at diagnosis has a
well-known association with hereditary breast cancer (26, 27). Peterson et al, for
example, found that younger patients were more likely to have a positive family
history (28). Lynch et al found that patients with a positive family history were
5more likely to be young (26). In spite of the commonly accepted correlations
between young age and IBTR and between young age and hereditary breast
cancer, few studies have examined the variable of family history in
conservatively treated breast cancer patients and its possible relationship to local
relapse.
Clustering of breast cancer within families has been recognized for
centuries, with reports dating back to AD 100 (29). In the mid-nineteenth
century, the French surgeon Paul Broca noted that 10 out of 24 women over 5
generations died of breast cancer in his wife's family (29, 30). Family history is
well recognized as one of the most significant risk factors for breast cancer (31) ,
second perhaps only to increasing age. In a recent study of the Utah Population
Database, the odds ratio for an unaffected woman with a family member with
breast cancer was 2.45 if the relative was a first degree relative, 1.82 if second
degree, and 1.35 if third degree, illustrating a direct relationship between the risk
of breast cancer and the degree of closeness to the affected relative (31). The
same study estimates that 17% to 19% of breast cancer may be attributed to
family history (31).
Thus, according to the Utah study, no more than 20% of breast cancer in
the general population is linked to family history (31). In stark contrast, among
418 women with early-onset breast cancer (age 40 and younger), 40% had at least
one affected relative (first or second degree), demonstrating a clear relationship
between young age at diagnosis and hereditary breast cancer (32). For an
unaffected sister of a proband with breast cancer, her risk of breast cancer is
inversely proportional to the proband's age at diagnosis; the hazard ratio is 1.7 if
the proband was diagnosed at age 50, 2.7 if she was diagnosed at age 40, and 4.3
if she was diagnosed at age 30 (27). In 1990, Claus et al wrote, "In addition to a
6positive family history, age at onset is the strongest indicator of a possible genetic
subtype of breast cancer. . ." (27).
The genetics of breast cancer has recently been the focus of intense
investigation. Using linkage analysis in 23 large families, a locus for breast
cancer susceptibility was mapped to the long arm of chromosome 17 (17q21) and
called BRCAl in 1990 (33). The gene BRCAl was identified by positional cloning
in 1994 (34). Since then, mutations have been found throughout the gene (35).
Also in 1994, a second locus for hereditary breast cancer, called BRCA2, was
mapped to the long arm of chromosome 13 or 13ql2 (36). The next year, the gene
BRCA2 was identified (37, 38). Over 200 mutations have been identified in these
two genes. Commercial genetic testing for both BRCAl and BRCA2 mutations
became available through Myriad Genetics, Inc. in 1996.
The exact functions of BRCAl and BRCA2 remain unknown. Induced by
estrogen, BRCAl is a protein associated with the cell-cycle that suppresses cell
proliferation (39). BRCA2 is less well studied. Both BRCAl and BRCA2 are
considered tumor suppressor genes in that they encode for proteins that
negatively regulate tumor growth (34). One mutant or inactivated allele is
inherited in the germline leading to cancer predisposition. Later inactivation of
the wild-type allele (termed loss of heterozygosity) in somatic breast tissue
eventually leads to tumor growth (34). This transformation presumably occurs
because of a series of alterations in the DNA of ductal epithelial cells within the
breast (33).
The precise prevalence and penetrance of BRCAl/2 mutations have been
actively pursued over the few years subsequent to the identification of the two
genes. The majority of hereditary breast cancer is thought to be due to the
inheritance of a BRCAl or BRCA2 mutation (29, 36, 38). BRCAl is generally
accepted to account for 80% of hereditary breast and ovarian cancer. As a
7reference, approximately 10% of women with breast cancer have hereditary
breast cancer (28). According to initial penetrance studies, mutations in BRCAl
were reported to confer an 87% risk of breast cancer by age 70 (40). Similarly,
another study found that 88% of patients with BRCAl mutations developed
breast cancer by age 65 (41). In the general population, a woman has a lifetime
risk of breast cancer of roughly 10% (42). In BRCAl mutation carriers, the risk of
ovarian cancer is estimated to be 44% by age 70; the risks of colon and prostate
cancer are also increased (40).
Further insight into BRCAl and BRCA2 has come from mutation studies
of families of Ashkenazi Jewish descent. The Ashkenazi Jewish population,
whose ancestors lived in central and eastern Europe, appears to have a slightly
increased risk of breast cancer (29). In the United States, more than 90% of
Jewish people are of Ashkenazi descent (22). The deletion of adenine and
guanine at position 185 in codon 23 of exon 2 (185delAG) is one of the most
common known mutations in BRCAl (43). In a study of 858 unrelated
Ashkenazi Jewish patients who were seeking genetic testing for conditions
unrelated to cancer and who were not selected for family history, 0.9% of the
patients were heterozygous carriers of the 185delAG mutation as compared with
none of the 815 controls (44).
Struewing et al estimate that, among Ashkenazi Jewish women younger
than age 50, the 185delAG frameshift mutation accounts for 16% of breast cancers
and 39% of ovarian cancers (44). In contrast, in the non-Ashkenazi population all
BRCAl mutations only account for 4.1% of breast cancers and 12% of ovarian
cancers diagnosed before age 50 if a carrier frequency of 0.2% is assumed (44). In
a study from New York, the 185delAG mutation was estimated to account for
22% of early-onset breast cancer (defined as before age 42) among affected
Ashkenazi Jewish women (43). In a Boston study of women with early-onset
8breast cancer (age 40 and younger), FitzGerald et al found a 21% frequency of the
185delAG mutation in a subset of 39 Jewish patients (32). The authors estimate
that the risk of early-onset breast cancer is increased 27-fold in carriers of the
185delAG mutation (32), which affects approximately 1% of the Ashkenazi
Jewish population (44).
Research from Ashkenazi Jewish patients has also provided data on
penetrance. Interestingly, more recent population-based studies have estimated
the penetrance of BRCAl/2 mutations to be slightly lower than in the initial
studies, which were conducted in high-risk clinics (45). Among a Washington,
D.C. community-based group of Ashkenazi Jewish women with BRCAl/2
mutations, the risks of breast and ovarian cancer by age 70 were 56% and 16%,
respectively (46). Whereas in one study the penetrance of BRCAl mutations
equaled that of BRCA2 mutations (46), another study stated that BRCA2
mutations may contribute less than BRCAl to hereditary breast cancer (47).
Krainer et al suggest that BRCA2 mutations are less common in early-onset
breast cancer and may be less penetrant (47). The prevalence of BRCAl/2
mutations may also be less than initially thought (48). Couch et al identified
BRCAl mutations in only 16% of breast cancer patients with a positive family
history, which contrasts with the figure of 45% obtained from linkage analysis
(48). Another study found that 12.8% of 798 high-risk women had BRCAl
mutations (49). Couch et al propose that together BRCAl and BRCA2 may
account for only 40% to 50% of hereditary breast cancer (48).
Regardless of the differences in penetrance and prevalence between
selected families and the general population, the breast cancer susceptibility
genes are major contributors to early-onset breast cancer. The frequency of
BRCAl germline mutations in breast cancer patients with a young age at
diagnosis is estimated at approximately 10% to 13% (32, 48, 50). In a population-
9based study of early-onset breast cancer by Langston et al, 6 of 80 (7.5%) women
diagnosed with breast cancer before age 35 had germline BRCAl mutations (50).
Two of the mutations were found in women with no family history of breast or
ovarian cancer (50). Among women not selected for family history status,
Malone et al found the frequency of BRCAl mutations in women diagnosed with
breast cancer before age 35 to be 6.2% (12 of 193 patients) (51). In breast cancer
patients diagnosed before age 32, Krainer et al report a BRCAl germline
mutation rate of 12.3% (9 of 73 patients) (47). FitzGerald et al found that 13% of
women diagnosed with breast cancer before age 30 had definite deleterious
BRCAl mutations (4 of 30 patients) (32).
The identification of breast cancer susceptibility genes BRCAl and BRCA2
has raised many new questions. Over the past few years, the epidemiologic and
basic science research on BRCAl and BRCA2 has been extensive. Yet clinical
data on outcomes of various treatment modalities in patients with BRCAl/2
mutations are lacking. Sample sizes are small, and the follow-up has been short
because the availability of genetic testing is relatively recent. Consequently, little
is known regarding the appropriate management of hereditary breast cancer;
whether management should differ for hereditary as opposed to sporadic breast
cancer is not clear. Of note, the survival rates appear to be similar for hereditary
and sporadic breast cancer (22). While some authors have recommended that
patients with hereditary breast cancer should undergo simple mastectomy (42),
at the present time no evidence is available to indicate that a positive family
history is a contraindication to conservative treatment (28). However,
surprisingly few studies have looked at the efficacy of lumpectomy and radiation
therapy in patients with hereditary breast cancer. The precise frequency of IBTR
in patients with a positive family history is unknown.
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When examining outcomes in conservatively treated patients with
hereditary breast cancer, most studies have looked at family history status,
which serves as a surrogate although perhaps imperfect marker of hereditary
breast cancer. In 1988, Kurtz et al noted that a positive family history was not
associated with an increase in IBTR; the recurrence rate was not significantly
different for patients with a positive family history (17%) versus those with a
negative family history (24%) (18). More recent studies have also found no
difference in local recurrence rates between patients with a positive family
history and patients without a family history following treatment with
conservative surgery and radiation therapy (22, 28, 52, 53). A retiospective study
from Fox Chase Cancer Center found that family history was not a prognostic
factor in younger patients, and no differences were found in either IBTR rate or
survival based on family history (28). Similarly, in a recent study from the
University of Pennsylvania, no difference in IBTR rate was observed among
patients age 40 and younger with a positive family history compared to matched
controls without a family history (52). The Joint Center for Radiation Therapy
also found no difference in IBTR rate or survival in young patients (age 36 or
younger) with and without a positive family history (22). Finally, a study from
Stanford UniversityMedical Center showed no differences in freedom from local
recurrence at 5 years for patients with a first degree family history, patients with
any family history, and patients with no family history (53).
The majority of the studies published to date have found no negative
effect of family history on outcome in conservatively treated patients. Only two
studies have found an association between family history and local relapse; both
studies were limited to patients with ductal carcinoma in situ (54, 55). In the
first, 40% of patients (4/10) with IBTR had a positive family history, compared to
11.4% of patients (5/44) without IBTR (54). In the second study, the 10-year
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actuarial rate of IBTR was 37% in patients with a positive family history (n=17),
compared to 9% in patients with a negative family history (n=58) (55). However,
the number of patients in both studies was small. The only study to have
demonstrated any negative effect of family history on survival in conservatively
treated patients was from the University of Chicago (56). Overall survival was
worse in patients over age 50 with a positive family history (defined as one first
degree relative) as compared to patients over 50 with no family history (56).
Family history had no effect on outcome in younger patients or on IBTR rates at
any age (56).
The consensus based on little available data holds that no direct
relationship exists between family history and local recurrence. Nonetheless, the
issue of management of hereditary breast cancer is far from resolved. Studies of
patients with documented BRCAl/2 mutations treated with lumpectomy and
radiation therapy are both limited and conflicting (57 - 60). Initial concerns
regarding radiation-induced carcinogenesis appear thus far to be unfounded. On
the other hand, one could hypothesize that BRCAl/2 mutations may render the
breast tissue more sensitive to radiation (22). A retrospective study by Gaffney et
al showed no adverse effects of radiation therapy in patients with BRCAl/2
mutations (61). Survival at 5 years was similar for these patients and matched
controls with sporadic breast cancer (61). However, 88% of the 56 patients
underwent mastectomy (61). No study has conclusively demonstrated that
conservative treatment is inappropriate in patients with BRCAl/2 mutations.
The exact risk of local relapse in these patients has not been firmly established.
Based on the aforementioned studies, the risk of local recurrence appears
to depend upon age at diagnosis. The role of family history in local recurrence is
unclear and may be difficult to elucidate given the close association of early-
onset breast cancer and hereditary breast cancer. Whether conservative
12
management with lumpectomy and radiation therapy is appropriate for patients
with a strong family history is unknown. Conservative management in patients
with known BRCAl/2 mutations is even less well studied.
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STATEMENT OF PURPOSE
The present study of breast cancer patients treated with lumpectomy and
radiation therapy serves three distinct purposes. The first objective was to assess
the long term outcome of conservatively treated patients at Yale-New Haven
Hospital, focusing on any association between age and local recurrence. The
second purpose was to explore the relationship between family history and local
relapse. To accomplish this goal, a case-control study design was used. In a
subgroup of the database patients, family history status was compared between
case patients who had experienced an IBTR and carefully matched control
patients who had not experienced an IBTR. The third purpose of this study was
to ascertain the frequency of BRCAl/2 mutations in the group of index patients
with IBTR, hypothesizing that it may be higher in the case patients than in the
controls. The current study aims to improve the current understanding of how
young age at diagnosis, family history, and BRCAl/2 mutations contribute to the
risk for recurrent breast cancer following conservative surgery and radiation
therapy.
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METHODS
Long term outcome. The medical records and pathology reports of 984
breast cancer patients treated between 1970 and 1990 in the Department of
Therapeutic Radiology at Yale-New Haven Hospital were thoroughly reviewed
to assess long term outcome. This extensive review process was performed by
author BH and others. All patients had American Joint Committee on Cancer
(62) clinical stage 0, 1, or II breast cancer and were treated with conservative
surgery and radiation therapy to the intact breast. Surgical management
consisted of lumpectomy with or without axillary lymph node dissection (2).
During the time span of the study, detailed analyses of the surgical margins were
not routinely performed. Radiation therapy was delivered to the intact breast
along with regional nodal irradiation as clinically indicated at the discretion of
the treating radiation oncologist. Radiation therapy was administered using
standard techniques with 4 to 6 Mev photons, with a daily fraction size of 2.0 Gy
to a total median dose to the intact breast of 48 Gy. When treated, the regional
lymph nodes received a total median dose of 46 Gy. An electron boost was
routinely administered resulting in a total tumor bed dose of 64 Gy. Adjuvant
systemic cytotoxic chemotherapy and adjuvant hormonal therapy were each
employed as clinically indicated in accordance with standard practices during
this time interval. Patients were treated with systemic therapy with
standardized regimens but not on prospective protocols. Patients were followed
at least twice yearly for the first 5 years after treatment and at least annually
thereafter. Annual mammography was a routine part of the follow-up program.
Diagnostic studies for systemic metastasis were performed as clinically
indicated, at the discretion of the treating physicians.
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All patient data were recorded and entered into a computerized database
by author BH and others. Data consisted of demographics, age and stage at
diagnosis, tumor size, tumor histology (infiltrating ductal, infiltrating ductal and
intraductal, intraductal, lobular, tubular, medullary, or other), axillary lymph
node status, estrogen receptor status, progesterone receptor status, radiation
treatment, adjuvant chemotherapy, adjuvant hormonal therapy, as well as
outcomes including local, regional, and distant metastasis. Endpoints included
biopsy-documented ipsilateral breast tumor relapse (IBTR), biopsy-documented
regional nodal relapse, clinically evident distant metastasis, and patient status
(alive or dead, with or without active disease). IBTR was defined as a breast
cancer recurrence anywhere within the treated breast. Overall survival refers to
survival with or without disease recurrence. Survival curves were calculated
using the standard life table method, with differences between curves tested by
the Mantel-Haenszel chi-square statistic and the log-rank statistics test.
Univariate and multivariate analyses were performed using the Cox regression
model.
Family history. Previous studies have retrospectively evaluated the
relationship between family history and IBTR using data already recorded in
their databases. For this study, family history information available in the
medical record and in the radiation therapy chart was deemed incomplete and
unsuitable for a detailed analysis. Furthermore, family history information may
have changed over time given the long term follow-up in this series. Obtaining
detailed family history pedigrees for all 984 patients in the database, although
ideal, was not feasible given available resources. Thus, a case-control study
design was chosen to evaluate the relationship between family history and local
recurrence in a cohort of conservatively treated breast cancer patients.
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Patients from the computerized database who had experienced a local
recurrence in the conservatively treated breast were identified as potential study
participants. A total of 112 patients had experienced a biopsy-documented local
recurrence and had undergone salvage surgery at the time of recurrence.
Patients who were lost to follow-up, patients who were contacted but refused to
participate, and patients who had died were excluded due to the need for
informed consent and the nature of the study. Fifty-two patients with IBTR who
were alive and willing to participate comprised the index population for the
case-control study. All patients in the study were from the original database of
conservatively treated patients and were included in the long term follow-up
study with the exception of eight index cases and eight control patients
diagnosed after 1990. Author EH carefully matched the 52 index patients to 52
control patients from the database who had not experienced a local or distant
relapse. After a rigorous review of each medical record, patients were matched
based on various criteria, including age at diagnosis (within 5 years), year of
diagnosis (within 5 years), race, the presence of bilateral breast cancer, clinical
presentation (mammogram, physical exam, or both), primary tumor size,
primary tumor histology, axillary lymph node status, surgical margin status,
estrogen receptor status, adjuvant chemotherapy, and adjuvant hormonal
therapy. Patients were intentionally not matched based on Ashkenazi Jewish
ancestry, which would tend to equate the family history results.
For each of the 104 patients in the study, informed consent was obtained
and a peripheral blood sample was drawn for future DNA analysis. With each
patient, author EH conducted a detailed family history interview using the
format and techniques employed by genetic counselors in the Cancer Genetic
Counseling Shared Resource at Yale. For patients who no longer resided near
the institution, arrangements were made with a local physician for the
17
phlebotomy procedure, and the family history interview was conducted by
telephone.
All family history information elicited from the interview was recorded in
the form of a pedigree, along with any relevant data obtained from a thorough
review of the medical record. The pedigree included parents, siblings, and
children (first degree relatives); grandparents, aunts, uncles, nieces, nephews,
and grandchildren (second degree relatives); and cousins (third degree relatives)
of the proband. For each family member identified, the pedigree showed the
year of birth, current age or age at death, the cause of death, the age at diagnosis
of any cancers, the location and type of cancer, whether the cancer was bilateral,
how the cancer was treated, and ethnic background including Ashkenazi Jewish
ancestry. The proband was asked about any history of chronic diseases,
carcinogen exposure including smoking, and changes in health status since last
seen at Yale. Other information recorded on the pedigree included male breast
cancer, retinoblastoma, prophylactic surgeries (i.e. mastectomy, oophorectomy,
hysterectomy), genetic disorders, congenital malformations (i.e. cleft lip, cleft
palate, club feet), mental retardation, infant deaths, miscarriages, consanguinity,
and carcinogen exposure including radiation, smoking, and occupational
hazards. Any other more distant relatives with cancer were also recorded.
Other studies have employed various methods of quantifying family
history, including counting the absolute number of affected relatives, calculating
risk scores, and using ratios to adjust for small family size (31). However, the
detailed pedigree used in this study is in many ways a superior method for
evaluating hereditary cancer risk. The pedigree offers an overall sense of the
family history, taking into account both family size and the age of onset of any
cancers. It allows the genetic counselor to see obvious patterns of inheritance
which may be obscured when a family history is simplified, for example, to the
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number of affected relatives (63). As an illustration (63), a woman may have a
mother and a grandmother with breast cancer and no other affected relatives. In
many models, she would be scored as having one first degree and one second
degree relative. However, if she is an only child and her mother is an only child,
her cancer risk may be more substantial than if she comes from a large family.
The pedigree was chosen as the method of assessment for this study because it
clearly shows the proportion of at-risk individuals who developed cancer in a
family.
After all family history data were gathered by author EH, the pedigrees
were analyzed by a genetic counselor (EM) who was blind to the clinical history
of the patients. Author EM is in the Cancer Genetic Counseling Shared Resource
at Yale and is certified by the American Board of Genetic Counseling. Each
pedigree was scored as "not suggestive", "moderately suggestive", or "highly
suggestive" of a hereditary breast cancer. Factors indicative of a hereditary
cancer include early onset, multiple primaries in the same patient, and multiple
cases of the same or similar types of cancer in closely related family members
(48). In addition, the genetic counselor scored each pedigree as "consistent" or
"not consistent" with a BRCAl or BRCA2 mutation in an attempt to predict the
presence of a mutation based on the inheritance pattern. This evaluation was
based on criteria used in genetic testing decisions, including an autosomal
dominant pattern of inheritance, high penetrance, Ashkenazi Jewish ancestry,
multiple cases of breast or ovarian cancer, early onset of breast cancer, or
bilateral breast or ovarian cancer (42, 48, 49).
For the two separate evaluations, differences in the categorical variables
were tested using a Pearson's chi-square analysis to compare the family history
status of the case group and the control group. A probability value of less than
0.05 was considered statistically significant.
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BRCAl/2. At the same time as the family history interview, informed
consent was obtained for genetic testing. All parts of the present study were
approved by the Human Investigation Committee of the Yale University School
of Medicine (HIC #9307). Each patient was assigned a unique identification
number to maintain confidentiality. The study participants were not informed of
the results of the genetic testing. Blood was collected from each patient for
lymphocyte DNA extraction and purification as previously described (49). All
blood samples were sent to Myriad Genetics, Inc. (Salt Lake City, Utah) for
complete sequencing of the BRCAl and BRCA2 genes from the isolated genomic
DNA. The unique identification number was used for all communication with
Myriad Genetics, Inc.
As described by Myriad Genetics Laboratory (64), aliquots of DNA were
subjected to polymerase chain reaction (PCR) amplification, with 35 reactions for
BRCAl and 47 reactions for BRCA2. The products of the amplification were then
directly sequenced in the forward and reverse directions. Potential variants were
confirmed by repeated PCR amplification and sequencing. Full sequence
determination for BRCAl included approximately 5,500 base pairs (23 exons; 22
coding, 1 non-coding) and 800 adjacent non-coding intronic base pairs. Full
sequence determination for BRCA2 included 10,200 base pairs (26 exons) and 900
adjacent non-coding intronic base pairs. All mutations that resulted in truncated
BRCAl or BRCA2 protein were considered deleterious. In addition, the
IVS8+2T->A mutation in BRCAl which results in a truncated protein through
aberrant splicing and the Y42 missense mutation in BRCA2 were considered
deleterious (35, 49, 65).
DNA sequencing was performed on the 52 index cases. Comparing the
frequency of mutations in this study to figures reported from high risk clinics
would be inappropriate because the present patient population was not selected
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based on family history or genetic risk. Similarly, comparisons cannot be made
with other databases of BRCAl/2 populations because the treatment method
and the length of follow-up may be different from that of the patients in this
study. The most logical control group for comparison is the database from which
the index patients were drawn. Thus, the control patients for the 15 index cases
who were age 40 and younger at diagnosis were also tested for BRCAl/2
mutations. The availability of funds limited the number of patients who could
undergo testing. Given the low frequency of deleterious BRCAl/2 mutations in
the index patients over age 40 (2 of 38 patients; see below), the likelihood of
finding a significant number of mutations in the control patients over age 40 was
exceedingly small.
McNemar's Y statistic for a matched-pair sample was used to test for
differences in the frequency of BRCAl and BRCA2 mutations between the case
group and the control group. A probability value of less than 0.05 was
considered statistically significant.
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RESULTS
Long term outcome. The characteristics of the patient population are
displayed in Table 1. As of September of 1997, the median follow-up was 12.3
years for the 984 patients in the database. The majority of the patients were age
50 or older at diagnosis (67.8%). Most tumors were Tl (69.8%) and infiltrating
ductal (53.7%) or infiltrating ductal and intraductal (19.9%). Of the 984 patients,
406 (41.3%) had negative axillary lymph nodes, whereas 417 (42.4%) had no
lymph node dissection. Four hundred ten patients (41.7%) were estrogen-
receptor positive, and 354 patients (36%) had no evaluation, reflecting that in the
early years of the study receptors were not routinely tested. Chemotherapy was
given to 171 patients (17.4%), and tamoxifen was given to 174 patients (17.7%).
22
Table 1. Characteristics of the Patient Population (n=984)
Characteristic # of Patients Percent
Age at diagnosis
35 and younger 64 6.5
36 to 49 253 25.7
50 and older 667 67.8
Tumor size
TO 42 4.3
Tl 687 69.8
T2 243 24.7
T3 11 1.1
T4 1 0.1
Tumor histology
Infiltrating ductal 528 53.7
Infiltrating ductal & intraductal 196 19.9
Intraductal 99 10.1
Infiltrating lobular 49 5.0
Tubular 19 1.9
Medullary 17 1.7
Other 76 7.7
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Table 1. Characteristics of the Patient Population (n=984)
(continued)
Characteristic # of Patients Percent
Nodal status
Positive
Negative
No dissection
Estrogen receptor status
Positive
Negative
No evaluation
Adjuvant chemotherapy
Yes
No
Adjuvant hormonal therapy
Yes
No
161 16.4
406 41.3
417 42.4
410 41.7
220 22.4
354 36.0
171 17.4
813 82.6
174 17.7
810 82.3
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Figure 1 illustrates the overall survival curve for the database with the
standard error. The actuarial overall survival is 73% at 10 years. The 10-year
distant metastasis-free survival is 78%, and the 10-year breast relapse-free
survival is 85%.
Overall Survival
Figure 1. Overall survival curve. The 10-year survival is 73%.
25
Table 2 shows actuarial outcome statistics with the standard error at 5
years and at 10 years for overall survival, distant metastasis-free survival, and
breast relapse-free survival.
Table 2. Long Term Outcome
Outcome 5 Years 10 Years
Survival .88 ± .01 .73 ± .02
Distant metastasis-free survival .88 ± .01 .78 ± .02
Breast relapse-free survival .94 ± .01 .85 ± .02
Of the 984 patients in the database, 112 have experienced a local relapse in
the conservatively treated breast resulting in an actuarial breast relapse rate of
15% at 10 years. The 10-year survival following breast relapse and salvage
mastectomy is 69%. When evaluated as a continuous variable in a Cox
regression model, age strongly correlated with IBTR, with young age predicting
for high local relapse rates (p < 0.005). Radiation dose, adjuvant chemotherapy,
adjuvant hormonal therapy, tumor size, nodal status, margin status, and young
age were assessed in a multivariable model. In this multivariate analysis, only
young age maintained statistical significance.
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Although age was tested in the Cox model as a continuous variable,
Figure 2 separates the breast relapse-free survival curves into two age groups for
purposes of illustration. The standard error is also shown. The difference
between the two breast relapse-free survival curves using age 40 as a cutoff is
statistically significant (p < 0.001).
Breast Relapse-Free Survival as a Function ofAge
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Figure 2. Breast relapse-free survival curves as a function of age.
(Forty and younger versus older than forty).
1C
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Actuarial data for breast relapse-free survival broken down into age 40
and younger versus over age 40 are shown in Table 3a. Table 3b divides the data
into age 35 and younger, between ages 36 and 49, and age 50 and older. The
standard error is also shown.
Table 3a. Breast Relapse-Free Survival by Age
Age at Diagnosis 5 Years 10 Years
40 and younger .82 ± .04 .70 ± .05
Older than 40 .96 ± .01 .88 ± .02
Table 3b. Breast Relapse-Free Survival by Age
Age at Diagnosis 5 Years 10 Years
35 and younger .87 ± .05 .74 ± .08
36 to 49 .90 ± .02 .82 ± .03
50 and older .96 ± .01 .88 ± .02
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Family history. The various criteria on which the case-control match was
based are shown in Table 4. The 3 African-American cases were matched to 3
African-American controls, and the 11 cases with bilateral breast cancer were
matched to 11 controls with bilateral breast cancer. The median age at diagnosis
in the case group was 49.5 years (range 29 to 81 years), and the median age in the
control group was 51.0 years (range 31 to 74 years). None of the patients
included in the family history study had documented positive margins. No
significant differences between the two groups were found for any of the
variables on which the case-control match was based, indicating that the two
groups were comparable.
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Table 4. Comparison of Cases (n=52) and Controls (n=52)
Variable Cases Controls
51
12.0
4
30
18
17
14
21
4
Median age (yrs.) 49.5
Median follow-up (yrs.) 14.6
Nodal status
Positive 6
Negative 19
No dissection 27
Estrogen receptor status
Positive 21
Negative 15
No evaluation 16
Documented negative margins 8
Adjuvant chemotherapy 9
Adjuvant hormonal therapy 5
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The following figure (Figure 3) is an example of a pedigree from the study.
It depicts the family history of a patient whose pedigree was scored as highly
suggestive of a hereditary breast cancer, as well as consistent with a mutation in
BRCAl or BRCA2. The proband, who was not of Ashkenazi Jewish descent, was
diagnosed with breast cancer at age 28. Her mother who was an only child was
diagnosed with breast cancer at age 33. Her paternal grandmother, who most
likely represents a sporadic case, was diagnosed with breast cancer at age 70.
Q
&
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o = stillbirth
ft = unilateral breast cancer
Figure 3. Sample pedigree. The arrow indicates the proband. Cousins, nieces,
and nephews of the proband were recorded but are not shown. Additional data
for each family member, including the current age or age at death and the cause
of death, were also recorded but are not shown (See Methods).
SAB = spontaneous abortion.
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The genetic counselor (EM), who was blind to the clinical history of the
patients, analyzed and scored each pedigree as not suggestive, moderately
suggestive, or highly suggestive of a hereditary breast cancer. The results of the
pedigree analysis for hereditary breast cancer are shown in Table 5. Using chi-
square analysis, no significant differences between the case group and the control
group were found. Although the number of highly suggestive pedigrees is
slightly higher in the case group than in the control group, this trend is not
statistically significant.
Table 5. Number of Pedigrees Suggestive of Hereditary Breast Cancer
Cases (%) Controls (%)
Not suggestive 28 (53.8) 27 (51.9)
Moderately suggestive 13 (25.0) 20 (38.5)
Highly suggestive 11 (21.2) 5 (9.6)
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The genetic counselor (EM) also scored each pedigree as consistent or not
consistent with a mutation in BRCAl or BRCA2. These results are illustrated in
Table 6. The case group and the control group had exactly the same number of
pedigrees scored as consistent with a BRCAl/2 mutation. The difference in the
number of Ashkenazi Jewish patients in each group is also not statistically
significant, as shown in Table 6.
Table 6. Number of Pedigrees Consistent with BRCAl/2 Mutations
Cases (%) Controls (%)
Not consistent 31 (59.6) 31 (59.6)
Consistent 21 (40.4) 21 (40.4)
Ashkenazi Jewish 11 (21.2) 5 (9.6)
Another common tool for evaluating family history is to compare the
number of patients who have a first degree relative with breast cancer (31).
Using this method, 13 out of 52 cases (or 25%) and 11 out of 52 controls (or 21%)
had a first degree relative with breast cancer, a difference which is not
statistically significant.
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BRCAl/2. The case group, which consisted of 52 patients who had
experienced an IBTR, underwent genetic testing for BRCAl and BRCA2
mutations. Deleterious mutations were found in 8 of the 52 index patients (15%).
The mutations were found predominately in younger women. The 15 case
patients who were diagnosed with breast cancer at age 40 and younger had a
mutation rate of 40% (6 of 15), as compared with a rate of 5.26% (2 of 38) in case
patients older than age 40 (p < 0.001).
The 15 case patients who were diagnosed with breast cancer at age 40 and
younger were compared to the 15 control patients to whom they had been
matched in the family history study. The mutation rate was 40% (6 of 15
patients) in the IBTR group, as compared with 6.7% (1 of 15 patients) in the
control group (p < 0.03125), as shown in Table 7. The mean age at diagnosis for
the 15 patients in the case group was 34.4 years (± 1.0), and the mean age at
diagnosis for the 15 matched controls was 37.1 years (± 0.7). The difference
between the mean ages is statistically significant (p < 0.006). Missense mutations
of unknown significance, also shown in Table 7, were found in 33.3% of the case
patients (5 of 15) and 26.7% of the control patients (4 of 15) , a difference which is
not statistically significant.
Table 7. BRCAl/2 Mutations in Patients Age 40 and Younger
Cases (%) Controlsm
Deleterious mutations 6 (40.0) 1 (6.7)
Missense mutations 5 (33.3) 4 (26.7)
34
Several comparisons were made between the IBTR patients with
BRCAl/2 mutations and the IBTR patients without mutations. First, the mean
age at diagnosis was 36 years (± 3.4) for the 8 patients who were mutation
carriers but was 52 years (± 2.0) for the 44 patients without germline mutations (p
< 0.002). Second, the mean time to IBTR was 8.7 years (± 1.9) in the 8 patients
with BRCAl/2 mutations, versus 4.7 years (± 0.5) in the other 44 patients with
IBTR (p = 0.03). Five of the 8 patients with IBTR and BRCAl/2 mutations had
bilateral breast cancer (62.5%). Out of the other 44 patients with IBTR, only 3 had
bilateral breast cancer (6.8%). Of note, all 8 patients with BRCAl/2 mutations
underwent successful salvage mastectomy at the time of local relapse and remain
alive without evidence of disease with a median follow-up of 7.7 years after
IBTR.
Analysis of the pedigrees of the 8 IBTR patients with BRCAl/2 mutations
reveals that 75% (6 of 8) had a family history which was highly suggestive of
hereditary breast cancer and consistent with a BRCAl/2 mutation. However,
25% (2 of 8) had pedigrees which were neither suggestive of hereditary breast
cancer nor consistent with a BRCAl/2 mutation. Two of the 8 patients with
mutations were of Ashkenazi heritage.
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Figure 4 is an example of a pedigree from an index patient in the study
who was found to be a carrier of a BRCA2 mutation but whose family history
was clearly not suggestive of a hereditary breast cancer. The proband was not of
Ashkenazi descent. She was diagnosed with unilateral breast cancer at age 57
and contralateral breast cancer at age 73. Her mother died at the age of 92 with
no sign of breast or ovarian cancer. Her sister is currently alive and well at the
age of 78. As illustrated in Figure 4, she had multiple unaffected aunts on her
father's side and one on her mother's side.
D | O □ 1 O
□ OU SAB
0 = Bilateral breast cancer
Figure 4. The pedigree of a patient with a BRCA2 mutation. The arrow indicates
the proband. As in the previous pedigree, further information was recorded but
is not shown here. SAB = spontaneous abortion.
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Figure 5 shows a pedigree from a patient in the study whose family
history was scored as highly suggestive of a hereditary breast cancer as well as
consistent with a mutation in BRCAl or BRCA2. However, she was not a
mutation carrier. Not of Ashkenazi descent, the proband was diagnosed with
unilateral breast cancer at age 34 and contralateral breast cancer at age 41. Her
mother was diagnosed with ovarian cancer at age 51. Her maternal aunt was
diagnosed with breast cancer at age 36. Another maternal aunt was diagnosed
with ovarian cancer at age 52. Although not shown in Figure 5, the proband also
had a cousin and a great-aunt with ovarian cancer, as well as a great-aunt and a
second cousin with breast cancer, all of whom were on her mother's side of the
family.
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Figure 5. The pedigree of a patient without a BRCAl/2 mutation. The arrow
represents the proband. As in the previous pedigrees, further information was
recorded but is not shown here. This pedigree is highly suggestive of a
hereditary breast cancer and a BRCAl/2 mutation. SAB = spontaneous abortion.
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DISCUSSION
Studies have now conclusively shown that conservative management is an
effective alternative to mastectomy for most women with early stage breast
cancer. As the number of patients opting for breast preservation has grown,
local recurrence has become an increasingly important clinical issue. The present
study seeks to define how age at diagnosis, family history, and BRCAl/2
mutations may relate to local recurrence in breast cancer patients treated with
lumpectomy and radiation therapy.
In the present study, analysis of long term follow-up data reveals that
young age at diagnosis is associated with a higher local relapse rate. This
difference is highly significant for patients age 40 and younger (p < 0.001). As
shown in Figure 2, older patients have a much better breast relapse-free survival
curve. Although tested as a continuous variable, age 40 was chosen as a cutoff
for illustration purposes. Age 40 has also frequently been used as a dividing line
in the literature (18, 52). Kurtz et al state that for their patient population, the
"threshold for breast recurrence risk is properly defined at 40 years" (18). The
survival statistics reported in the current study are consistent with previous
studies (12). The explanation for the correlation between young age and local
relapse has not been firmly established. In this study as in other studies, the
association of young age with local relapse was not related to the primary tumor
size, axillary nodal status, estrogen receptor status, or other factors commonly
linked to metastatic potential. Whether the higher IBTR rate in young patients is
somehow connected to the hormonal environment or another molecular marker
has not been elucidated. Clearly, however, the association between young age
and IBTR is strong and holds out in multivariate analysis. From this study and
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others, one may conclude that young age at diagnosis is a significant
independent risk factor for IBTR following lumpectomy and radiation therapy.
Given the known connection between hereditary breast cancer and early-
onset breast cancer (26, 27), one might hypothesize that the higher IBTR rate in
young patients may be associated with family history. Several investigators have
attempted to address this issue, but no definite relationship between family
history and IBTR has been reported. Most of the studies to date, however, have
not approached the question using a detailed and current family history pedigree
analysis as was done in the present study. Given that medical records and
radiation charts may be incomplete, and given that family history may change
over time, family history was reassessed in a rigorous fashion for each patient in
the case-control study.
The detailed family history study showed no direct correlation between
family history and IBTR. Specifically, no significant differences in family history
status were found between patients who had experienced a local relapse and
patients who had not. These results are in agreement with previous studies
which have observed that family history status may not be a prognostic indicator
for local recurrence (18, 22, 28, 52, 53, 56). Whereas the present study examined
family history in patients with and without local recurrence, one recent study
looked at the issue from another angle, comparing IBTR rates in patients with
and without a positive family history (52). No difference in the IBTR rate was
found among patients age 40 and younger with a positive family history when
compared to similar controls (52). Survival also did not differ according to
family history status (52). In women with early stage breast cancer, a family
history of breast cancer does not thus far appear to be a contraindication for
conservative surgery and radiation therapy.
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One potential problem with the use of the personal interview for eliciting
family history information is that it relies on the human memory which can be
unreliable. Confirmation of reported cancers in each relative through medical
records and pathologic documentation would improve the present study but was
not feasible. A patient's family history should be verified whenever the family
history data will affect clinical management. Similarly, records should ideally be
obtained in epidemiologic studies to ensure the accuracy of results which may be
applied to clinical management. Research has shown that patient interviews are
not completely accurate (66). A study by Love et al examined the accuracy of
family history by comparing patient reports to medical records (66). The
accuracy of the proband in identifying a primary cancer site decreased as the
relative became more distant, from 83% to 67% to 60% for first, second, and third
degree relatives, respectively (66). When patients were incorrect, they often
identified a metastatic site as the primary site (66). Importantly, however,
probands were correct 91% of the time for all relatives with breast cancer,
whether close or distant (66).
The majority of the results in the present study were based on the
proband's ability to report a family history of breast cancer. Assuming from the
Love study that the patients were 91% accurate at reporting breast cancer, the
results presented here would be unlikely to change with proper documentation.
In addition, the case-control study design equalizes the potential for recall bias;
sensitization to family history is unlikely to have been associated specifically
with the cases or with the controls. However, a patient with a family history of
cancer conceivablymay have been more interested in the study and therefore
more likely to participate.
Early onset of sporadic breast cancer is relatively rare, as is bilateral breast
cancer; both are associated with hereditary breast cancer. For example, Kurtz et
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al reported that patients younger than age 40 were both more likely to have a
family history of breast cancer and more likely to develop contralateral breast
cancer (18). Chabner et al found that patients with a positive family history were
significantly more likely to have contralateral breast cancer, with a relative risk of
5.7 (22). In another study, women who developed contralateral breast cancer
within 3 years of the original diagnosis were 10 times more likely to have a first-
degree relative with breast cancer (31). In the present study, variables on which
the case-control match was based included age and the presence of bilateral
breast cancer, which may have led to similar family histories between the two
groups. The patients were not, however, matched on the basis of Ashkenazi
Jewish ancestry. Because Ashkenazi heritage alone can predict for genetic
mutations, matching for this variable would have confounded the results and
possibly skewed the relationship between local recurrence and BRCAl/2
mutations.
The correlation between mutation status and family history is not always
complete. Whereas DNA analysis gives information about one or two genes,
family history encompasses multiple genes which may interact either with each
other or with environmental factors to modify a patient's risk and influence her
phenotype. A strong family history is not always necessary in order for a patient
to have a BRCAl/2 mutation. Indeed, the early onset of breast cancer, in the
absence of family history, has been shown to be an independent predictor of
mutations in these genes (48, 50). FitzGerald et al found that women with early-
onset breast cancer may have germline BRCAl mutations without a strong
family history (32). Langston et al also found that the risk of harboring a BRCAl
mutation was not limited to patients with strong family histories of breast or
ovarian cancer (50).
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When a mutation is detected in a patient without a significant family
history, the family may have had few individuals at risk for breast cancer due to
its structure or due to deaths at an early age. Two of 8 patients with BRCAl /2
mutations in the present study had pedigrees that were neither suggestive of a
hereditary breast cancer nor consistent with a BRCAl/2 mutation. One of these
pedigrees is shown in Figure 4. Several explanations for this pedigree are
possible. The family may have a germline mutation that is less penetrant. Other
genes in the family may modify the expression of BRCAl/2 (50). The family
history may have been inaccurate. Or the mutation may have been in the
germline but new rather than inherited; one study found germline BRCAl
mutations in 5.7% of patients with sporadic breast cancer (67).
On the other hand, a remarkable family history does not always accurately
predict the presence of a BRCAl/2 mutation. Researchers have been surprised
to find no mutation in patients with an extraordinarily strong family history (35).
Cases such as these imply that factors other than BRCAl and BRCA2 also play a
role. Studies have found that approximately 10% to 20% of families with highly
suggestive pedigrees have no mutation in the known breast cancer genes (29).
The pedigree in Figure 5 illustrates an example of a patient in the study who has
no BRCAl/2 mutation but has multiple family members with breast and ovarian
cancer. A different highly penetrant gene or multiple genes with variable
penetrance may be responsible (29, 32). Another less likely possibility is that this
patient represents a sporadic case of bilateral breast cancer within a family who
carries a BRCAl mutation (29). Or, a BRCAl/2 mutation could lie in a non-
coding region and be undetectable with commercial genetic testing (48). Finally,
this patient's family may share a non-genetic risk factor, or the cluster of cancers
in her family may simply be due to chance.
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The recent identification of the breast cancer susceptibility genes, BRCAl
and BRCA2, was a monumental milestone in breast cancer research. Clearly
many unanswered questions remain. For example, a woman with a germline
mutation in one of these genes may respond differently to radiation. Or she may
be at higher risk for a second primary tumor or a local recurrence following
radiation. Advances in technology, such as genetic testing, often predate the
understanding of the biology and clinical relevance of scientific discoveries. To
address the relationship between local relapse and BRCAl/2 mutations, the third
part of the present study was undertaken to investigate whether patients with
IBTR may have a higher mutation frequency than controls.
For the 52 patients who had experienced a local relapse, the BRCAl/2
mutation rate was 15% (8 of 52 patients). Six of these 8 mutations were found in
patients age 40 and younger, which is consistent with the known association
between BRCAl/2 and early-onset breast cancer. The BRCAl/2 mutation rate
for patients diagnosed with breast cancer at age 40 and younger was 40% (6 of 15
patients) in the IBTR case group, versus 6.7% (1 of 15 patients) in the control
group. Although the sample size was small, the mutation rate of 40% is
surprisingly high even when compared to the results of studies from high risk
clinics. As a reference, among Boston women diagnosed with breast cancer
before age 30, only 13% (4 of 30 patients) were found to have a definite BRCAl
mutation (32), which is significantly less than the 40% observed in patients age 40
and younger in the present study. Only 2 of the 8 IBTR patients with BRCAl /2
mutations were of Ashkenazi Jewish descent. The high mutation rate in the IBTR
patients thus cannot be explained by an over-representation of Ashkenazi Jewish
patients in the database. The case-control match for the 15 case patients age 40
and younger was imperfect, simply due to a lack of very young control patients
in the database. Every effort was made to match the cases and controls as closely
43
as possible, but the mean age of the case group (34.4± 1.0) was less than the mean
age of the control group (37.1± 0.7); this difference was statistically significant (p
< 0.006). The greater mutation frequency in the case group may be explained in
part by their slightly younger age. Nonetheless, finding an elevated frequency of
BRCAl/2 mutations in patients who experienced IBTR following lumpectomy
and radiation therapy may have important clinical implications.
Some key distinctions were found when comparisons were made between
the patients with IBTR who were BRCAl/2 mutation carriers and the patients
with IBTR who were not mutation carriers. The mean age of the patients with
IBTR and BRCAl/2 mutations was significantly less than the mean age of
patients with IBTR and no mutation, a result which is consistent with the well
established association between these mutations and early-onset breast cancer.
Further, the mean time to IBTR was significantly longer in the patients with
mutations (8.7 years versus 4.7 years) which implies that the IBTR may represent
a new primary rather than a clonogenic recurrence. True recurrences, as
opposed to second primaries, typically occur within the first few years after
diagnosis (68).
Several investigators have made observations indicating that early IBTR
and late IBTR may represent separate entities and that late IBTRs may in fact be
new primary tumors. Studies have found that early local recurrences are
associated with a poor prognosis when compared to late local recurrences (9, 13,
14, 17). For example, Fourquet et al found that local recurrences occurring within
3 years of initial diagnosis were aggressive tumors and were often accompanied
by a simultaneous lymph node recurrence or distant metastasis (9). Whelan et al
also found that IBTR within a year of surgery was associated with an increased
risk of distant metastasis and mortality (17). In another study the risk of
developing distant metastasis was 6.6 times higher in patients who had an IBTR
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in the first year as compared to patients who had an IBTR more than 3 years later
(14). Haffty et al report a 5-year post-IBTR survival rate of only 50% if the IBTR
was within 4 years of diagnosis, but the survival rate was 78% if the IBTR
occurred more than 4 years later (68). Interestingly, in the same study patients
with true local recurrences had decreased survival compared to patients whose
IBTR was classified as a probable second primary (68).
Two additional observations from present study suggest that the late
IBTRs in the patients with BRCAl/2 mutations may represent second primaries.
First, the location within the breast of the IBTR was distinct from the location of
the original tumor in the majority of the 8 patients with mutations as compared
to the IBTR patients without mutations (data not shown; 65). In 1981, Vilcoq et al
observed that more than half of the IBTRs occurred in quadrants different from
the original tumor and theorized that they may have been second primaries (15).
Second, the histology of the IBTR was different from the histology of the original
tumor in most of the patients with mutations as compared to the patients
without mutations (data also not shown; 65). These findings are consistent with
the hypothesis that late IBTRs are second primaries in the BRCAl/2 mutation
carriers (68).
The issue of local recurrence in BRCAl /2 mutation carriers has not been
extensively studied in the literature. Marcus et al found a lower recurrence rate
in BRCAl-related hereditary breast cancer patients as compared to other
hereditary breast cancer patients (69). In another study of 49 Dutch patients,
local recurrence rates and overall survival were similar for BRCAl-associated
and sporadic breast cancer patients at 5 years (57). However, a later study from
the same group demonstrated a higher IBTR rate in hereditary breast cancer
patients, which they defined as either a documented BRCAl/2 mutation or at
least 3 first degree relatives with breast or ovarian cancer (58). The difference
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between the hereditary cases and the sporadic controls became apparent at 5
years and then continued to increase; the IBTR rate reached 27% at 10 years and
48% at 13 years (p=0.09) for the hereditary cases (58). Their conflicting results
may be explained by inadequate follow-up in the first study. Taken together,
their findings also suggest that these late IBTRs may be second primaries, which
is consistent with the results of the present study. Similarly, Marcus et al found
the cumulative incidence of second primary tumors to be 38% after 10 years in
patients with BRCAl-related hereditary breast cancer (26 families with 157 breast
cancers) (69). Robson et al report an IBTR rate of 12% in patients with BRCAl/2
mutations, but the median follow-up was only 6.6 years (59). This follow-up
time is most likely too short given that the mean time to IBTR in the present
study was 8.7 years in the patients with BRCAl/2 mutations.
The possibility that a late IBTR represents a new primary is not surprising
given the high lifetime risk of contralateral breast cancer in BRCAl/2 mutation
carriers. Five of the 8 patients (62.5%) with IBTR and BRCAl/2 mutations had
contralateral breast cancer. This figure (62.5%) may be higher than in other
studies, but the median follow-up for detecting these contralateral events was
over 12 years in the present patient population. Looking at 33 families, Ford et al
estimated the risk of contralateral breast cancer in BRCAl-mutation carriers to be
48% by age 50 and 64% by age 70 (40). For comparison, in a study of 410 patients
not selected for family history or BRCAl/2 mutations, the risk of contralateral
breast cancer was 5.4% with a median follow-up of 11 years (10). Verhoog et al
found the risk of contralateral breast cancer to be 25% after 5 years in patients
with BRCAl mutations, which was four to five times the risk in control patients
with sporadic breast cancer (57). Similarly, an abstract from Memorial Sloan-
Kettering Cancer Center reported that contralateral breast cancer had occurred in
7 of 25 (28%) patients with BRCAl/2 mutations at 5 years (59). The same group
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reported in another study a 5-year contralateral breast cancer-free survival rate of
69% among patients with mutations, versus 96% among patients without
mutations (60).
The identification of BRCAl and BRCA2 has focused increasing attention
on determining the most appropriate treatment for hereditary breast cancer. The
results of this study indicate that carriers of BRCAl/2 mutations who undergo
lumpectomy and radiation therapy may be at high risk for both ipsilateral and
contralateral events, implying that bilateral mastectomy may be a legitimate
primary treatment option. Susceptibility to cancer is inherited in the germline.
One copy of the mutation is present in every cell within the residual breast
tissue, including the untreated breast. Oncogenesis then takes place when a
somatic mutation occurs in the other copy of the gene (33, 34). Given these
concepts, the high risk of further events in patients with germline mutations is
not unexpected. One may theorize that a primary bilateral mastectomy may
decrease the risk of future events. However, no conclusive evidence is currently
available to support this hypothesis. The survival benefit of a bilateral
mastectomy as initial treatment is unknown, particularly since the late IBTRs and
contralateral cancers have not been shown to influence survival in these patients.
If future research confirms both that a BRCAl/2 mutation is a prognostic
factor for IBTR and that these patients should be managed differently from
sporadic cases, commercial genetic testing may become more useful for the
clinical oncologist. Genetic testing will be especially helpful if family history
does not perfectly reflect the presence of a mutation, as observed in this study.
Six of the 8 patients with BRCAl/2 mutations had pedigrees which were scored
as highly suggestive of a hereditary breast cancer and consistent with a
BRCAl/2 mutation. However, the correlation was not complete because 2
patients had mutations in the absence of a family history, and several patients
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without mutations had highly suggestive pedigrees. The findings in this and
other studies (32, 50, 51) suggest that family history alone may be unreliable and
insufficient for predicting the presence or absence of a BRCAl/2 mutation.
The issue of genetic testing is complex. Interestingly, Struewing et al point
out that the 1% prevalence of the 185delAG mutation among Ashkenazi Jewish
women is higher than many of the genetic diseases for which routine screening is
in place (44). The utility of genetic testing at present is limited for several
reasons. A negative result in an unaffected woman is uninformative unless a
known mutation has previously been identified in her family. A positive result
in an unaffected patient would encourage closer surveillance. She may have
mammography starting at an earlier age, she may be more diligent with self
breast exams, and she may have more frequent clinical breast exams. She may be
monitored with trans-vaginal ultrasounds, pelvic exams, and CA-125 levels to
screen for ovarian cancer. Unfortunately, whether these measures confer any
survival benefit for patients with BRCAl/2 mutations has yet to be determined.
Once a specific mutation has been identified in an unaffected patient,
knowledge of its precise penetrance would be beneficial for both the clinician
and the patient. The exact risk of breast cancer in carriers of 185delAG and other
mutations is unknown because most studies reporting penetrance have either
been conducted in linkage-analysis families or in high-risk clinics, both of which
may be biased towards patients carrying highly penetrant mutations (35, 45).
Penetrance estimates from community-based populations have been much lower
(46). Future studies will establish the exact penetrance of each mutation and will
resolve the question of allelic heterogeneity, in which specific mutations may
confer distinct risks of breast and ovarian cancer at different ages (35, 40).
Survival may also depend upon the position of a mutation (57), further
emphasizing the importance of these future studies.
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If the results of the present study are replicated and bilateral mastectomy
is proven to be the preferred treatment for patients with BRCAl/2 mutations,
one can envision the application of genetic testing to breast cancer treatment
decisions in the future. For example, if a woman diagnosed with breast cancer is
either very young or has a family history highly suggestive of a BRCAl/2
mutation, then perhaps genetic testing would be recommended at the time of
diagnosis to determine appropriate clinical management. Genetic testing may be
particularly useful in young Ashkenazi Jewish women with breast cancer in
whom the pretest probability of a mutation is high.
Still, receiving a diagnosis of cancer has many psychological ramifications.
Most patients may be overwhelmed if simultaneously faced with the diagnosis of
breast cancer, the option of genetic testing, and the possibility of a bilateral
mastectomy. Furthermore, not all women will wish to undergo genetic testing.
Genetic testing may lead to the loss of insurance, job discrimination,
psychological distress, and family disturbances (48, 63). Consequently, for many
patients, their family history and their clinical data will be the only sources of
information available to the clinician when management decisions are made (22).
This study and others have shown that family history is in some cases an
imperfect predictor of BRCAl/2 status. However, in the future clinicians may
increasingly utilize predictive models, such as that proposed by Couch et al, to
inform a woman of her odds of carrying a mutation (48).
Universal recommendation of bilateral mastectomy to patients with
BRCAl/2 mutations is not warranted at this time. But given the data available to
date, unilateral mastectomy is probably not any more effective than conservative
treatment because the contralateral breast is still at risk. A clinical trial
randomizing breast cancer patients with BRCAl/2 mutations to unilateral
mastectomy, bilateral mastectomy, and lumpectomy with radiation therapy
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would be the most ideal method to evaluate these treatment options. In addition
to obtaining survival data, one could also establish the effects of radiation
therapy in these patients. For example, to see if radiation has a detrimental or
prophylactic effect on the contralateral breast, rates of new contralateral cancers
in the conservative treatment group would be compared to rates in the unilateral
mastectomy group. Such a trial would require large numbers of patients and
follow-up over many years. Currently the scarcity of data evaluating outcome
for conservatively treated patients with BRCAl/2 mutations reflects the
relatively recent discovery of the genes and the need for long term follow-up for
accurate assessment. The findings in this study strongly emphasize the
importance of adequate follow-up because the average time to IBTR was more
than 8 years in mutation carriers.
The role of adjuvant therapy in patients with BRCAl/2 mutations has not
been established. None of the 15 patients age 40 and younger who experienced
IBTR were treated with tamoxifen. Several studies have suggested that adjuvant
therapy may decrease the rate of IBTR in general (3, 5, 23, 24). Fisher et al
reported that in patients with positive axillary nodes who received adjuvant
chemotherapy, the cumulative incidence of IBTR was only 5% after 12 years of
follow-up (5). In a multivariate analysis Kim and colleagues reported that
postoperative adjuvant therapy with tamoxifen was independently associated
with better IBTR-free survival rates (24). Similarly, data from Haffty et al suggest
that adjuvant therapy, whether cytotoxic or hormonal, may lead to lower IBTR
rates (3).
The National Surgical Adjuvant Breast and Bowel Project (NSABP) found
that in patients without breast cancer, prophylactic tamoxifen reduced the risk of
invasive breast cancer by 49% (70). Through 69 months of follow-up, the
cumulative incidence of breast cancer was 22.0 per 1000 in the tamoxifen group
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(n = 6707) versus 43.4 per 1000 in the placebo group (n = 6681) (70). Whether
these benefits would be seen in BRCAl/2 mutation carriers is not known.
Tamoxifen is not without risk; in the NSABP trial it increased the rate of
endometrial cancer with a risk ratio of 2.53 (70). Rates of stroke, pulmonary
embolism, and deep vein thrombosis were also increased (70). Thus, the risks
and benefits must be weighed for each patient. Younger patients are more likely
to have estrogen receptor-negative tumors (23, 52, 53), and tamoxifen did not
decrease the rate of estrogen receptor-negative tumors in the NSABP trial (70).
BRCAl-associated breast cancer is also more likely to be estrogen receptor-
negative which may limit the efficacy of tamoxifen in these patients (57, 60). On
the other hand, no evidence is available to indicate that the target cell lacks
receptors prior to malignant transformation in patients with BRCAl/2 mutations
(71). Selective estrogen receptor modulators (SERMs) may still have a role for
prevention in young patients, even if tamoxifen may be less effective as a
treatment. Currently, the efficacy of tamoxifen in primary prevention or for
decreasing second events among carriers of BRCAl and BRCA2 mutations is
unknown.
In addition to chemoprevention, prophylactic mastectomy and
prophylactic oophorectomy are options for high risk women; however, little
information is available on long term outcome following these procedures (72).
The potential benefit of surgical prophylaxis depends upon the patient's risk of
cancer and her prognosis if diagnosed with a particular tumor-type, as well as
any psychological benefit of anxiety-reduction (72). Prophylactic surgery does
not completely eliminate risk, as breast cancer can occur in residual tissue
following mastectomy (45), and ovarian cancer has been reported following
oophorectomy (40). In a retrospective study conducted at the Mayo Clinic,
bilateral prophylactic mastectomy reduced the incidence of breast cancer by at
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least 90% in patients (n=639) with a positive family history (73). Two major
groups have constructed decision analyses to assess prophylactic mastectomy in
patients with BRCAl/2 mutations. In the first, Schrag et al estimate that a 30-
year old woman with a BRCAl/2 mutation would gain 2.9 to 5.3 years of life
expectancy from the procedure depending on her cumulative cancer risk (72).
The estimated risk reduction of a prophylactic mastectomy was assumed to be
85% (72). In the second, Grann et al conclude that prophylactic mastectomy at a
young age improves survival and is cost-effective but provides little
improvement in quality of life unless the genetic risk is very high (74). When
employing such a decision analysis in the clinical setting to guide a woman at
high risk for breast cancer, reliable data on the outcomes of the procedure are
indispensable. Estimates regarding the gain in life expectancy from a
prophylactic surgery are highly dependent on assumptions of its efficacy (73). A
randomized trial of tamoxifen versus prophylactic mastectomy versus
surveillance would be the most ideal approach to evaluate these methods of
breast cancer prevention. However, such a study is unlikely to be undertaken
given the radical differences among the treatment groups and the number of
years of follow-up necessary to obtain valid data (73).
To assess the clinical implications of the present BRCAl/2 study, its
limitations must be taken into consideration. First, the sample size is small. A
total of 67 patients underwent mutation analysis. Ideally, all 52 control patients
would have undergone genetic testing rather than only the 15 control patients
age 40 and younger. However, the likelihood of finding a significant number of
mutations in the control patients who were over age 40 is extremely small. The
study may also be subject to selection bias. BRCAl-associated breast cancer has
been reported have the same prognosis as sporadic breast cancer (39, 60, 75).
However, one recent study suggests that survival may be better in breast cancer
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patients with BRCAl mutations (41). If this observation is correct, then the
frequency ofmutations in the present study may be biased because young
women without mutations may have died. Similarly, the frequency ofmutations
may be underestimated in the present study if BRCAl/2 mutations are
associated with decreased survival. Another possible source of selection bias
relates to the poor prognosis of early IBTR. Some of the patients with early IBTR
may have died and thus may not have been included in the study.
One must also consider the current lack of knowledge regarding the
significance of missense mutations. DNA can be altered in numerous ways, and
only certain mutations have been classified as deleterious (For review, see 35). A
frameshift mutation, in which nucleotide(s) are added or deleted, alters the
reading frame and is usually deleterious. Intron/exon splice-site mutations and
regulatory mutations can also occur. A nonsense mutation occurs when a
nucleotide substitution leads to a stop codon. On the other hand, a missense
mutation occurs when a single nucleotide substitution changes the amino acid
but does not affect further translation. The challenge lies in ascertaining which
amino acid substitutions are clinically meaningful (35).
In the present study, any mutation which resulted in a truncated protein
was considered deleterious. However, several sequence variants of unknown
functional significance were also identified. Missense mutations were found in 5
of 15 case patients and 4 of 15 control patients diagnosed at age 40 and younger
(p = NS). Interpreting the role of missense mutations with one amino acid
substitution is difficult because most are probably polymorphisms with no
functional significance. Testing affected relatives of the proband for the missense
mutation may be helpful because cosegregation would imply but not prove
causality (35). Missense mutations that are common in the general population
are unlikely to be causal (49). But some missense mutations may affect protein-
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protein interactions and thus be predisposing mutations (49). In the future
functional assays will assist in assessing the contribution of these mutations to
the development of breast cancer.
Clinical application of the present results is not warranted at this point.
Larger studies are necessary to replicate and confirm these findings before
incorporating them into clinical practice. Malone and colleagues eloquently
state, "While the research community continues to probe questions of genetic
susceptibility, there remains no substitute for access to high-quality, affordable
health care that provides for vigilant screening and early diagnosis for all
women" (51). As additional data are gathered on the biology and the natural
history of BRCAl /2-associated breast cancer, patients and clinicians will become
better equipped to make management decisions.
This study opens up several avenues for future research. To investigate
further the late IBTRs which occurred in patients with BRCAl/2 mutations,
clonality studies using genetic markers to test the tumor tissue would be help to
differentiate true recurrences from second primaries. Point mutations in the
tumor may theoretically serve as markers, and the relapse tumor may be
compared to the primary to establish clonality (68). The development of strict
criteria for distinguishing between true recurrences and second primaries would
facilitate the interpretation of data on prognostic factors for IBTR. For example,
the overexpression of HER-2 neu oncoprotein previously linked to IBTR may
either be associated with clonogenic relapses or may predict for second primaries
(21).
Another question to be addressed is whether patients with BRCAl/2
mutations are at higher risk for chest wall relapses following mastectomy. If the
risk of local relapse is increased, then the risk of chest wall relapse may also be
increased. However, given the hypothesis of the present study that the IBTRs are
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second primaries, a high rate of chest wall relapses would not be expected.
BRCAl-associated tumors have distinct pathologic characteristics, including a
high frequency of medullary tumors, a high proliferative fraction, less ductal
carcinoma in situ, and a tendency toward aneuploidy (For review, see 39). As
the biology of BRCAl /2-associated breast cancer becomes more clearly defined,
perhaps tumor pathologic characteristics will eventually be incorporated into
decisions regarding genetic testing and treatment.
Future studies may find other genetic markers that are risk factors for
local relapse in conservatively treated breast cancer. In families with Cowden
disease or Li-Fraumeni syndrome, the genetic contribution to IBTR is unknown
(29). Cowden disease is a rare autosomal dominant familial cancer syndrome
which has been associated with breast cancer (29). Also autosomal dominant, Li-
Fraumeni syndrome is another rare cancer predisposition syndrome which
results from a germline mutation in the p53 tumor suppressor gene (76).
Families have a high incidence of soft tissue sarcomas, osteosarcomas, leukemias,
brain tumors, as well as breast cancers (76).
Other low-penetrance susceptibility genes may also contribute to breast
cancer and local relapse. Ataxia-telangiectasia is an autosomal recessive
syndrome in which homozygotes have a 100-fold increased risk of developing
cancer (29, 77). One percent of the general population is thought to be
heterozygous for the ataxia-telangiectasia gene (ATM); some studies have
suggested that heterozygosity in the ATM gene increases a woman's risk for
breast cancer (77). The HRAS1 variable number of tandem repeats (VNTR)
polymorphism site is located 1 kilobase downstream from the HRAS1 proto-
oncogene on chromosome 11 or Hpl5.5 (78). Rare alleles of this VNTR may
modify the expression of other cancer susceptibility genes (78). Phelan et al
found that the risk of ovarian cancer was 2.11 times greater for BRCAl mutation
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carriers who also had a rare HRAS1 allele, demonstrating for the first time that a
modifying gene may alter the penetrance of a cancer predisposition syndrome
(78).
The focus of future biochemical and genetic studies will be on BRCAl,
BRCA2, and perhaps more common but less penetrant genes. Other yet
undiscovered breast cancer susceptibility genes may prove to be important
prognostic factors for local recurrence. The variable penetrance of BRCAl/2
suggests that other factors must have a role in the development of breast cancer
in susceptible individuals. Further studies are needed to determine the
hormonal, dietary, and environmental factors, and even other genetic loci which
may play a part in breast cancer and which may alter the risk associated with the
known susceptibility genes.
Several conclusions may be drawn from the current study. First, the
results of the database analysis clearly show that young age at diagnosis is a
significant independent risk factor for local recurrence following lumpectomy
and radiation therapy. Young women appear to have a more locally aggressive
breast cancer, independent of stage or metastatic potential. The explanation for
this finding is yet unclear and warrants further investigation to elucidate the
relevant molecular mechanisms. Second, in a case-control study no significant
association was found between family history and local recurrence; in agreement
with previous studies, these results imply that a positive family history is not a
contraindication to conservative management. The third part of the study
sought to define the relationship between IBTR and BRCAl/2 mutations. The
mutation rate was unexpectedly high (40%) in index patients age 40 and younger
with IBTR compared to matched controls. A patient with a mutation in BRCAl
or BRCA2 may be at risk for a second primary in the treated breast as well as in
the contralateral breast, which has important implications for management
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decisions. This second primary hypothesis is supported by clinical and
pathologic observations, including the length of time to IBTR as well as the
distinct location and histology of the tumors. Of note, the incongruity between
the family history results and the BRCAl/2 mutation results suggests that family
history alone may not be a sufficient indicator of BRCAl or BRCA2 status. The
findings of the present study contribute to the current understanding of how
young age at diagnosis, family history, and BRCAl/2 mutations relate to local
relapse following conservative surgery and radiation therapy in early stage
breast cancer patients.
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